Drawing for VIBRANZ

USPTO serial 87646725

VIBRANZ

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
CROWLEY, SEAN MICHAEL
Law office
GENERIC WEB UPDATE

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VIBRANZ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous systemABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 19, 2018MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION—
Apr 19, 2018ABN5ABANDONMENT - AFTER PUBLICATION—
Apr 17, 2018EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Jan 11, 2018ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jan 2, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 2, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 13, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 26, 2017ALIEASSIGNED TO LIE—
Nov 9, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 9, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Nov 9, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 9, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 9, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 3, 2017DOCKASSIGNED TO EXAMINER—
Oct 25, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 19, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance